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Abstract
Background: Epithelial-mesenchymal transition (EMT) is the key process driving cancer metastasis. Oncogene/self
renewal factor BMI-1 has been shown to induce EMT in cancer cells. Recent studies have implied that noncoding
microRNAs (miRNAs) act as crucial modulators for EMT. The aims of this study was to determine the roles of BMI-1
in inducing EMT of endometrial cancer (EC) cells and the possible role of miRNA in controlling BMI-1 expression.
Methods and results: We evaluated the expression of BMI-1 gene in a panel of EC cell lines, and detected a
strong association with invasive capability. Stable silencing of BMI-1 in invasive mesenchymal-type EC cells up-
regulated the epithelial marker E-cadherin, down-regulated mesenchymal marker Vimentin, and significantly
reduced cell invasion in vitro. Furthermore, we discovered that the expression of BMI-1 was suppressed by miR-194
via direct binding to the BMI-1 3’-untranslated region 3’-UTR). Ectopic expression of miR-194 in EC cells induced a
mesenchymal to epithelial transition (MET) by restoring E-cadherin, reducing Vimentin expression, and inhibiting
cell invasion in vitro. Moreover, BMI-1 knockdown inhibited in vitro EC cell proliferation and clone growth,
correlated with either increased p16 expression or decreased expression of stem cell and chemoresistance markers
(SOX-2, KLF4 and MRP-1).
Conclusion: These findings demonstrate the novel mechanism for BMI-1 in contributing to EC cell invasion and
that repression of BMI-1 by miR-194 could have a therapeutic potential to suppress EC metastasis.
Introduction
Endometrial cancer (EC) is the most frequent gynecolo-
gic malignancy in the developed countries [1]. Although
the incidence of EC is lower in East Asian than in Wes-
tern countries, it tends to increase markedly in recent
years [2]. EC is generally classified as type I endome-
trioid EC or type II non endometrioid EC based on
etiology and clinical variables. The majority of EC are of
type I, which are associated with good prognosis. How-
ever, myometrial invasion and distant metastasis
decreases the survival rates of patients after surgical
treatment. In contrast, type II EC is often related to
poor prognostic factors, such as high grade or deep
myometrial penetration. Thus, to further improve
patient survival, it is essential to further understand the
molecular and cellular mechanism of EC development,
and in turn, to develop novel therapeutic strategies to
block EC progression.
The epithelial to mesenchymal transition (EMT) is a key
process contributing to cancer metastasis, characterized by
the loss of the epithelial marker E-cadherin, an increase in
the mesenchymal markers Vimentin and N-cadherin, and
an increase in the migratory and invasive behavior [3].
BMI-1 (B lymphoma mouse Moloney leukemia virus
insertion region 1) is a self-renewal gene and overex-
pressed in multiple human cancers, including lung cancer
[4], breast cancer [5], prostate cancer [6], ovarian cancer
[7], and recently EC [8]. BMI-1 upregulation is associated
with malignant transformation in hepatocellular carci-
noma [9]. Notably, recent research has shown that BMI-1
plays essential roles in inducing EMT in head and neck
squamous cell carcinoma [10]. However, the roles of BMI-
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ing BMI-1 expression remain to be investigated.
Epigenetic alterations (methylation, non-coding micro-
RNA) are critical to cancer development [11]. Micro-
RNAs (miRNAs) are regulatory, single-stranded non-
coding RNAs that repress protein expression by base-
pairing with the 3’ untranslated region (UTR) of the tar-
get mRNA, which triggers either mRNA translation
repression or RNA degradation [12]. Aberrant levels of
miRNA have been reported in a variety of human can-
cers, including EC [13]. These observations promote us
to hypothesize that certain miRNA may control BMI-1
expression in EC cells, and thus have a therapeutic
potential against EC cancer progression.
In this study, we provide experimental evidence that
BMI-1 is essential for EMT and invasive phenotype in EC
cells. We discovered a novel post-transcriptional regulatory
mechanism of BMI-1 expression mediated by miR-194 by
directly interacting with the BMI-1 mRNA at the 3’-UTR.
The expression of BMI-1 protein level was suppressed by
miR-194 with MET transition associated with reduced EC
tumor invasion. As a result, it provides a potential new
strategy to prevent EC progression by targeting oncogene
BMI-1.
Materials and methods
Cell lines
Human EC cell lines HHUA (well differentiated),
HOUA-I (moderately differentiated) and HEC-50B
(poorly differentiated) were obtained from RIKEN cell
bank (Tsukuba, Japan) and grown in Minimum Essential
Medium Eagle (Sigma-Aldrich, UK) supplemented with
15% of fetal bovine serum (Cambrex Bioscience, Bel-
gium). The cells were maintained at 37°C in a humidi-
fied atmosphere of 5% CO2.
Selection of invasive EC cells in transwell invasion
chamber
Subpopulations from HEC-50B cells were selected as
described previously [14], 6 using transwell plates.
Briefly, the polycarbonate membranes (containing 8-μm
pores) of the transwell inserts were coated with Matrigel
gel (BD Biosciences, CA). Cells were resuspended in
serum-free MEM and seeded into the upper wells.
MEM medium supplemented with 15% bovine serum
was placed into the lower chamber. Following incuba-
tion for 24 h at 37°C, the inserts were removed. The
cells that migrated through the membranes and attached
to the lower-chamber compartments were harvested
aseptically and named as HEC-50B-highly invasive (HI)
Western blot analysis
Whole cellular protein was obtained with M-Per Mam-
malian Protein Extraction Reagent (Pierce Biotechnology,
MA). The aliquots were separated on SDS-PAGE (10%)
and transferred to nitrocellulose membranes. Antigen-
antibody complexes were detected ECL blotting analysis
system (Amersham Pharmacia Biotech, UK). The BMI-1
antibody (ab38295) was purchased from Abcam (Cam-
bridge, MA). E-cadherin antibody (A01589) and Vimen-
tin antibody (A01189) were obtained from GenScript
(Edison, NJ). Antibody for p16 (sc-468) and GAPDH (sc-
47724) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Enforced miR-194 expression
HEC-50B-HI cells were transfected with 50 nM of pre-
cursor miR-194, or negative control precursor miRNA
(Ambion, Austin, TX) by use of Lipofectamine 2000
(Invitrogen, Carlsbad, CA). After 48 h, the cells were
processed for Western blot, invasion assay, proliferation,
or colony formation assay.
In vitro cell invasion assay
HEC-50B-HI transfected with precursor miR-194, or
negative control precursor miRNA were harvested 48 h
after transfection and re-suspended in serum-free MEM.
2×1 0
4 cells in 500 μl of MEM medium were added
into the upper chamber. In the lower chamber, 750 μl
of MEM medium containing 15% fetal bovine serum
and 10 μg/ml of bovine fibronectin (Invitrogen, Ger-
many) were placed. The cells were allowed to migrate
through the intermediate membrane for 24 h at 37°C.
Membranes were then fixed with 10% neutral-buffered
formalin and stained in 10% Giemsa solution. The cells
attached to the lower side of the membrane were
counted in ten high-powered (200×) fields under a
microscope. Assays were done in triplicate for each
experiment, and each experiment was repeated three
times.
MiRNA quantitative real-time reverse transcription PCR
Total RNA containing small RNA was extracted from
cell lines by TRIzol reagent (Invitrogen, CA) according
to the manufacturer’s instructions. Quantitative reverse
transcription (qRT)-PCR was performed to detect the
levels of hsa-miR-194 in three EC cell lines by NCode
miRNA qRT-PCR Analysis (Invitrogen, CA) according
to the manufacturer’s protocol. A qRT-PCR forward pri-
mer for hsa-miR-194 (5’-TGTAACAGCAACTC-
CATGTGG-3’) was designed and synthesized by
Invitrogen. GAPDH was used for normalization [15]. All
real-time PCR assays were conducted as previously
described [16].
Luciferase activity assay
The 3’-UTR vector of BMI-1 containing an intact miR-
194 recognition sequence was purchased from OriGene
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taining BMI-1 3’-UTR with point mutations in seed
sequence was constructed using a QuickChange site-
directed mutagenesis kit (Stratagene, CA), using the fol-
lowing primers: 5’-CATTACTTTTACATATATTGCT
GGCCCTTCTGCTTTC-3’ (forward) and 5’-GAAAG-
CAGAAGGGCCAGCAATATATGTAAAAGTAATG-3’
(reverse). Cells were transfected with 50 nM precursor
miRNA (miR-194, miR-128 or control miRNA) along
with the wild-type or mutant BMI-1 3’-UTR-luciferase
constructs. 24 hours after transfection, luciferase activity
was measured using dual-luciferase assay (Promega,
Madison, WI).
BMI-1 silencing by shRNA
BMI-1 shRNA plasmids (sc-29814-SH) and control
shRNA plasmids (sc-108060) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). HEC-50B-HI
cells were stably transfected as described previously [17].
In brief, cells at 70% confluency were transfected with
Lipofectamine PLUS Reagent (Invitrogen, CA) according
to the manufacturer’s protocols and selected in MEM
medium containing puromycin( S i g m a - A l d r i c h ,M O )a t
1 μg/ml 48 h post-transfection. Selected clones of HEC-
50B-HI cells were expanded into HEC-50B-HI-BMI-1
shRNA cells and HEC-50B-HI control shRNA cells,
respectively.
MTT assay
For measurements of cell proliferation rates, 1 × 10
3
cells were plated into each well of 96-well plates and
cultured in 100 μl of medium containing 10% serum.
After 1 or 5 days incubation, 10 μlo fM T Ts o l u t i o n
(Cell counting kit-8, Dojindo, Japan) 10 was added into
each well, and plates were incubated for 4 h at 37°C,
and 450 nm UV absorbance of each sample was mea-
sured in a microplate reader. Assay was done in tripli-
cate wells, and each experiment was repeated three
times.
Colony formation assay
About 500 cells were seeded per well in 6-well plates.
After 10 d, the cells were fixed in 70% ethanol and
stained with 10% Giemsa (Sigma- Aldrich, MO). Colo-
nies consisting of >50 cells were counted. The results
represented the average of three independent
experiments.
qRT-PCR of stemness markers and chemoresistance genes
Real-time RT-PCR was performed using a Primescript
One Step RT-PCR Kit (Takara, Japan). Primers used for
SOX-2, KLF4, MRP-1 and GAPDH were previously
reported [18].
Statistical analysis
All experiments were performed in triplicates. Statistical
analyses were performed using SPSS statistical software.
Student’s t-test was adopted. Significance was 11 defined
as P < 0.05.
Results
BMI-1 expression correlates with invasive potential and
EMT phenotype of EC cells
BMI-1 is thought to mediate cell invasion in several
types of cancer. To assess the role of BMI-1 in confer-
ring invasive properties to EC cells, we used Western
blot analysis to characterize expression of BMI-1 in four
human EC-derived cell lines (HHUA, HOUA-I, HEC-
50B and HEC-50B-HI), and determined whether expres-
sion of endogenous BMI-1 correlated with invasive abil-
ity by using an in vitro cell invasion assay. In contrast to
HHUA cells with markedly reduced endogenous BMI-1
expression, HEC-50B-HI cells expressing 5-fold higher
levels of BMI-1 protein exhibited the highest invasive
potential after 24 h incubation (Figure 1A). The number
of HEC-50B-HI cells that passed through the membrane
was 5.0 times larger than the number of HHUA cells
(Figure 1B), thus suggesting that BMI-1 expression level
seemed to be closely associated with the enhanced inva-
sive activities of EC cell lines.
It has been suggested that EMT plays a crucial role in
cancer metastasis [3]. 12 During the acquisition of EMT
characteristics, cancer cells lose the intercellular junc-
tions and gain fibroblast-like motile and invasive pheno-
type, associated with the down-regulation of epithelial
marker E-cadherin and the up-regulation of mesenchy-
mal marker Vimentin [3]. To test the hypothesis that
BMI-1 would be involved in the acquisition of an inva-
sive EMT phenotype in EC cells, we evaluated the mor-
phological changes between HEC-50B-derived aggressive
sub-cell lines and its parental HEC-50B cells. Highly
invasive HEC-50B-HI cells displayed spindle-like, fibro-
blastic morphology when comparing to HEC-50B cells
showing epithelial-like appearance (Figure 1C). In accor-
dance with this finding, expression of E-cadherin was
significantly reduced in HEC-50B-HI cells. In contrast,
expression of Vimentin was significantly increased in
this cell line (Figure 1D), demonstrating that up-regula-
tion of BMI-1 may contribute to EMT-derived invasive
phenotype in EC cells.
Silencing of BMI-1 expression reverts EMT phenotype and
reduces EC cell invasion
To validate whether BMI-1 affects EMT and cell inva-
sion of EC cells, HEC-50B- BMI-1 shRNA and control
shRNA cell lines were established. The BMI-1 protein
level was significantly decreased in BMI-1 shRNA-
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of BMI-1 protein seemed to change the morphology
from spread fibroblastoid to epithelial-like appearance
(Figure 2B), decreased cell invasion (Figure 2C), and
resulted in the up-regulation of E-cadherin and down-
regulation of Vimentin at protein levels (Figure 2D).
These results suggest that BMI-1 is critical for the
acquisition of EMT characteristics in EC cells.
MiR-194 directly targets BMI-1, and reverses EMT
phenotype in EC cells
Based on miR target analysis using TargetScan website
[19], miR-194 was identified as potential regulator of
BMI-1 expression. The predicted binding of miR-194
with BMI-1 3’UTR was illustrated (Figure 3A), indicat-
ing that miR-194 is a potential miRNA targeting BMI-1.
To compare the relationship between miR-194 and
BMI-1 expression, we examined the endogenous miR-
194 expression level by qRT-PCR in HEC-50B-HI and
HEC-50B cells. MiR-194 mRNA expression was
significantly lower in high BMI-1 expressing HEC-50B-
HI cells (Figure 3B), showing that miR-194 level inver-
sely correlated with BMI-1 expression. To examine the
inhibitory effect of miR-194 on BMI-1 protein level, we
performed Western blot analysis at 48 h after miR-194
transfection into HEC-50B-HI and HHUA cells. Ectopic
expression of miR-194 in these two cell lines signifi-
cantly decreased the protein levels of BMI-1 compared
to 14 control miRNA (Figure 3C).
To further confirm that BMI-1 is the direct target of
miR-194, firefly luciferase reporter vector containing a
segment of the 3’UTR of BMI-1 with point mutations in
the seed sequence was constructed. In addition, miR-
128 has been reported to target BMI-1 in glioma [20].
Therefore miR-128 was used as a positive control. The
BMI-1 luciferase constructs were then co-transfected
with miR-194, miR-128 or control miRNA into HEC-
50B-HI as well as HHUA cells. As expected, transfection
with miR-128 dramatically attenuated BMI-1 3’-UTR
luciferase activity. Interestingly, the BMI-1 3’-UTR
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Figure 1 Association between BMI-1 expression and invasive potential and EMT features of EC cell lines. A. BMI-1 protein levels in the
panel of EC cell lines were determined by Western blot analysis. B. Invasive ability of EC cells was evaluated by Matrigel invasion assays. Data
represent the mean ± SE of three independent experiments. C. Highly invasive HEC-50B-HI cells exhibiting fibroblastic morphology and the
parental HEC-50B cells showing epithelial-like appearance were fixed with neutral-buffered formalin, stained in Giemsa, and images were taken
(magnification × 100). D. Western blot analysis of epithelial marker E-cadherin and mesenchymal marker Vimentin in HEC-50B and HEC-50B-HI
cells.
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50B-HI and HHUA cells was significantly lower when
comparing with control miRNA-transfected cells,
whereas mutation of miR-194 recognition site rescued
the luciferase activity (Figure 3D). These results collec-
tively suggested a direct and specific inhibition of miR-
194 on BMI-1 3’-UTR in EC cells.
BMI-1 has been shown to promoting EMT in head
and neck squamous cell carcinoma [10], implies the
possibility that reexpression of miR-194 may lead to a
reversal of EMT phenotype of invasive EC cells. To test
our hypothesis, the effect 15 of ectopic expression of
miR-194 on cell invasion and expression of EMT mar-
kers was investigated in HEC-50B-HI and HHUA cells.
Transfection with miR-194 significantly decreased cell
invasion in these cells. However, this inhibition was
more evident in HEC-50B-HI cells (Figure 3E). Further-
more, transfection of miR-194 induced a loss of the
mesenchymal phenotype by restoring epithelial marker
E-cadherin and reducing mesenchymal marker Vimentin
expression (Figure 3C). These results indicated that
reexpression of miR-194 could reverse the EMT pheno-
type, and dramatically decreased cell invasion in BMI-1
expressing EC cells.
Knockdown of BMI-1 repressed in vitro cell proliferation
and clonal growth
It has been shown that BMI-1 is required for the clono-
genic growth of multiple myeloma cells [21]. Therefore,
we examined the roles of BMI-1 in regulating prolifera-
tion and colony growth of HEC-50B-HI cells. As
expected, cell proliferation was significantly decreased in
BMI-1 shRNA-transfected cells compared with control
cells (Figure 4A). Moreover, colony formation of HEC-
50B-HI cells was significantly reduced after BMI-1 pro-
tein expression was effectively suppressed by shRNA
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Figure 2 Silencing of BMI-1 expression reverts EMT phenotype and reduces EC cell invasion. A. Comparison of BMI-1 levels in un-
transfected HEC-50B-HI, HEC-50B-HI-BMI-1 shRNA and control shRNA cells. B. Morphological changes of HEC-50B-HI cells after knockdown of
BMI-1 expression 27 (magnification × 100). C. Effects of BMI-1 suppression on cell invasion ability using Matrigel invasion assay. Data represent
the mean ± SE of three independent experiments. *P < 0.01. D. Western blots of epithelial marker E-cadherin and mesenchymal marker Vimentin
in un-transfected HEC-50B-HI, HEC-50B-HI-BMI-1 shRNA and control shRNA cells.
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shown that BMI-1 promotes cell proliferation through
suppression of tumor-suppressor p16 [22], we deter-
mined the p16 protein level by Western blot. Down-reg-
ulation of BMI-1 expression by BMI-1 shRNA
transfection significantly increased p16 protein expres-
sion (Figure 4C). These results indicated that knock-
down expression of BMI-1 could suppress EC cell
proliferation and colony growth in EC cells by upregula-
tion of p16 expression.
Overexpression of BMI-1 in head and neck squamous
cell carcinoma promote stemness properties by increas-
ing the expression of stem cell marker and drug-resis-
t a n c eg e n e[ 1 8 ] .B yu s i n gq R T - P C R s ,w ed e m o n s t r a t e d
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Figure 3 MiR-194 directly targets BMI-1, and reverses invasive, EMT phenotype in EC cells. A. Sequence of miR-194 binding site in the
BMI-1 3’UTR predicted with TargetScan. B. MiR-194 expression levels in HEC-50B and HEC-50B-HI cells were determined by Real-time RT-PCR.
Data represent the mean ± SE of three independent experiments. *P < 0.01. C. Western blotting analysis of BMI-1, E-cadherin and Vimentin in
un-transfected EC cells and EC cells transfected with miR-194 or control miRNA. D. HEC-50B-HI and HHUA cells were transfected with WT or MT
BMI-1 3’UTR luciferase vectors, along with miR-194, miR-128 or control miRNA. Luciferase activity was measured at 24 h after transfection. Data
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194 or control miRNA was evaluated by Matrigel invasion assays. Data represent the mean ± SE of three independent experiments. *P < 0.01.
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compared with control shRNA cells (Figure 4D). These
results suggest the important roles of BMI-1 in modu-
lating cell proliferation and stemness in EC.
Discussion
Previous studies have linked BMI-1 upregulation to
enhanced cell invasion in various human tumors
[4-7]. However, the role of BMI-1 in EC cell invasion
has not been thoroughly explored. In this study, we
discovered that elevated BMI-1 expression closely
associated with EC cell invasion. In line with our
study, up- regulation of BMI-1 has been shown to
induce breast cancer metastasis [23]. Similarly, silen-
cing of BMI-1 can inhibit the metastatic capability of
cervical cancer cells [24]. Our results provided new
evidence to support the oncogenic roles of BMI-1 in
enhancing EC metastasis.
The acquisition of EMT-derived phenotype confers
invasive behavior of tumor cells. BMI-1 is able to induce
EMT in nasopharyngeal epithelial cells by repressing E-
cadherin expression and up-regulating Vimentin expres-
sion [25]. We showed for the first time that knockdown
o fB M I - 1i nE Cc e l l sl e dt oa na t t e n u a t i o no fin vitro
invasion and a reversion of EMT, evidenced by epithe-
lial-like morphology, increased expression of E-cadherin
and decreased expression of Vimentin. These findings
highlight the pivotal role for BMI-1 in driving invasive
potential in EC cells through induction of EMT
phenotype.
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Figure 4 Knockdown of BMI-1 repressed in vitro cell proliferation and clone growth. A. Effects of BMI-1 repression on cell proliferation
assessed by MTT assay in un-transfected HEC-50B-HI cells, HEC-50B-HI-BMI-1 shRNA and control shRNA cells. *P < 0.05. B. Colony formation was
assessed following stable repression of BMI-1. *P < 0.05. C. Western immunoblot analysis of p16 protein expression in un-transfected HEC-50B-HI
cells, HEC-50B-HI-BMI-1 shRNA cells and control shRNA cells. D. mRNA expression levels of SOX-2, KLF4 and MRP-1 in HEC-50B-HI-BMI-1 shRNA
and control shRNA cells were determined by Real-time RT-PCR. Data represent the mean ± SE of three independent experiments.
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modulation [26]. MiRNAs, such as miR-200 family and
miR-205, act as key modulators of EMT and enforcers
of the epithelial phenotype [27]. We showed that miR-
194 suppress BMI-1 expression through direct interac-
tion and inhibited EC cell invasion. These results were
c o n s i s t e n tw i t har e c e n tr e p o r tt h a tm i R - 1 9 4r e d u c e s
invasion of the mesenchymal-18 like liver cancer cells
both in vitro and in vivo [28]. The finding that BMI-1
expression was also reduced by overexpressing miR-194
in HHUA cells with low level of BMI-1 may reflect the
heterogeneity of EC. Sub-populations of this cell line
might be more aggressive and exhibit higher BMI-1
expression. Thus, targeting BMI-1 in invasive EC cells
by miR-194 would be valuable in development of new
therapeutic strategies against EC metastasis.
Cancer stem cell (CSC) has been demonstrated to play
important roles in cancer metastasis [3]. In many CSC
populations, aberrant BMI-1 expression is reported [29].
CSC isolated from EC has been shown to express BMI-
1 [30]. We demonstrated that knockdown of BMI-1 in
invasive mesenchymal EC cells significantly reduced in
cell proliferation, colony growth and up-regulated the
p16 tumor suppressor. Many independent studies also
support the association between BMI-1-dependent p16
suppression and enhanced stem cell proliferation [22].
Moreover, we demonstrated that loss of BMI-1 in EC
cells reduces expression of stemness gene SOX-2, KLF4
and drug-resistance gene MRP-1, suggesting that BMI-1
expression maybe required for the proliferation of can-
cer cells, as well as for regulation of stemness properties
of EC cells.
In conclusion, we discovered a critical function of
BMI-1 to potentiate EC metastasis via induction of
EMT. We also revealed a new regulatory mechanism of
BMI-1 expression by miR-194 to inhibit EC cell invasion
through down-regulation of BMI-1. As a result, restora-
tion of miR-194 expression could have important impli-
cations for the clinical management of EC.
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